Ligelizumab Is Superior to Omalizumab for Chronic Spontaneous Urticaria
- PMID: 32208012
- DOI: 10.1177/1203475419888873
Ligelizumab Is Superior to Omalizumab for Chronic Spontaneous Urticaria
Keywords: chronic spontaneous urticaria; chronic urticaria; ligelizumab; omalizumab.
Comment in
-
High-Dose Omalizumab versus Ligelizumab for the Treatment of Chronic Spontaneous Urticaria: Do Not We Need a Head-To-Head Comparison?Int Arch Allergy Immunol. 2021;182(5):461-462. doi: 10.1159/000512373. Epub 2020 Dec 15. Int Arch Allergy Immunol. 2021. PMID: 33321510 No abstract available.
Comment on
-
Ligelizumab for Chronic Spontaneous Urticaria.N Engl J Med. 2019 Oct 3;381(14):1321-1332. doi: 10.1056/NEJMoa1900408. N Engl J Med. 2019. PMID: 31577874 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical